PECAM1 and neoplasm: The groups with the baicalensis-treated patients showed significantly reduced expression of endothelial cell markers CD31 and α-SMA (smooth muscle actin protein found in almost all mammals) in tumors indicating that the drug inhibits tumor angiogenesis, disrupting the development of the vasculature.